PDS Biotechnology Financials - Benzinga

PDS Biotechnology Corp

PDSBNASDAQ

Trade with Public

Trade with Public

$0.2958

-0.0195-6.18%

Last update: Sep 11, 2:13 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

PDS Biotechnology Financials

PDS Biotechnology (PDSB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of $(0.21) per share

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of $(0.21) per share from

Benzinga Newsdesk

PRO
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

PRO
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M

Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and

Benzinga Newsdesk